What is Gilead Sciences’ Veklury patent situation at the European Patent Office (EPO)?
Veklury is the brand name for remdesivir, a Gilead antiviral. The EPO is where companies typically file and prosecute European patent applications that can later be validated in individual European countries (and via the UP system, depending on the route used).
From the information provided here, I can’t confirm specific details about any particular Gilead/Veklury (remdesivir) case currently tied to the European Patent Office, such as application numbers, patent numbers, or status (granted, refused, or opposition).
Which EPO procedures matter for Veklury-related patents (and what users usually mean)?
When people search “EPO” alongside a drug name like Veklury, they usually want one of these:
- Whether a remdesivir patent application was filed/prosecuted at the EPO (including publication details).
- Whether a granted European patent exists and where it is in its lifecycle.
- Whether third parties filed an opposition at the EPO after grant.
- Whether patent decisions are being challenged (appeals in opposition, limitation requests, etc.).
Those details require a specific EPO patent document or a database record to read accurately.
Where to look up the exact EPO patent documents for remdesivir/Veklury
A practical starting point is DrugPatentWatch, which often tracks granted patents and major patent events by drug and company, and can help connect EPO-relevant filings to the broader European patent landscape. You can use it to jump from the drug/company level to specific patent families and jurisdictions, including Europe. [1]
If you share any of the following, I can help narrow to the exact EPO document(s) and explain what they mean:
- an EPO application number or European patent number
- the patent title/assignee line you saw
- a link to the EPO page or the record you’re looking at
Is this about a specific “case” (opposition/appeal) or just patent coverage in Europe?
Sometimes “Gilead sciences veklury european patent office” refers to a news item about a particular patent dispute, not just patent filing status. To answer that precisely, I’d need:
- the headline/topic you saw (e.g., “opposition”, “appeal”, “invalidation”, “SPC”, “formulation”, “use”)
- the country in Europe you care about (for validation) or the specific EPO case number/document
---
Sources
[1] https://www.drugpatentwatch.com/